Surgical treatment significantly improves overall, 1-year, and 3-year survival rates for metastatic pancreatic adenocarcinoma, particularly in patients with liver-only metastases. Compared to chemotherapy and palliative care, surgical options reduce mortality risk (HR: 0.42). Despite promising results, outcomes vary based on metastatic sites, with no survival benefit observed for lung-only metastases. Further prospective trials are essential to validate findings and refine patient selection for surgical interventions.
Meta-Analysis by Tarek K, Amine TM (…) Tullio P et 4 al. in Langenbecks Arch Surg
© 2025. The Author(s).